User-Level Recall Due to Iron Particle Detection

Taiwan-based Sunny Pharmtech (6676) has initiated a voluntary recall of three lots of Cyclophosphamide for Injection, USP, supplied to the U.S. under the Longrove label, to the user level, effective July 24, 2026. The affected lots are 1g vials C23019V1 and C24015V1, and a 2g vial V24010V1, which were distributed to wholesalers, hospitals, and pharmacies between May and October 2024. The recall is due to the presence of iron particles in the product. The FDA notice states that intravenous administration of the contaminated product may cause phlebitis, granuloma, vascular occlusion, and life-threatening thromboembolic events. As of the date of the announcement, no adverse events or injuries related to the product have been reported. However, the expiration dates range from October 2026 to April 2027, necessitating immediate quarantine and recall of the remaining stock.

Marketed Generic: Pharmacology and Regulatory History

Cyclophosphamide is a generic version of the original brand, Cytoxan, and is an alkylating agent that alkylates the N7 position of guanine in DNA, creating cross-links and inhibiting cell replication. It is a marketed treatment approved for malignant lymphoma, multiple myeloma, leukemia, ovarian cancer, breast cancer, and steroid-resistant nephrotic syndrome in children. The initial U.S. approval was on November 16, 1959. Sunny Pharmtech's product, available in 500mg, 1g, and 2g single-use vials, received FDA abbreviated new drug application (ANDA) approval in October 2023. As an ANDA, which is a generic pathway that assesses equivalence to a reference drug, it did not require an advisory committee (AdComm) vote.

Supply Chain and Competitive Landscape

Sunny Pharmtech manufactures the product, and Longrove Pharmaceuticals licenses it for distribution in the U.S. Cardinal Health (CAH) manages the distribution, returns, and disposal. The FDA Orange Book lists several Cyclophosphamide injections from companies such as Baxter International (BAX), Hikma Pharmaceuticals (HIK), Sandoz Group (SDZ), and Dr. Reddy's Laboratories (RDY). Therefore, the discontinuation of a single supplier will not eliminate treatment options. However, as this drug is a key component of many combination chemotherapy regimens, mismatches in hospital contracts, formulations, or vial sizes may increase short-term procurement conversion costs and inventory burdens. Competitors have the opportunity to replace the recalled product, but their ability to supply a quality product quickly will determine the actual shift in market share.

Key Investment Considerations

DIResearch estimates the global Cyclophosphamide market at USD 734.87 million in 2025. As a mature generic market, sales are more sensitive to supply stability and maintenance of hospital channels than to price. While this action is limited to three lots and the FDA announcement does not mandate manufacturing cessation or facility sanctions, the detection of iron particles is a factor that customers will re-evaluate regarding the quality system and facility management of sterile injectables. Sunny Pharmtech is working with Longrove and Cardinal Health to manage the recall, reconciliation, and disposal, and return, disposal, and replacement costs may affect short-term profitability. The pace of recovery of trust in the U.S. injectable business will depend on the completion of the recall, the FDA's enforcement report, and the disclosure of any subsequent audits or corrective actions.